NOWHERE IS INDIA'S EPITHET-pharmacy of the world-more apt than in the case of some big pharmaceutical companies. One such company is Aurobindo Pharma, which has steadily grown over the past 10 years to become the second-biggest Indian pharma company behind only Sun Pharma. Its consolidated revenues grew from ₹4,550.56 crore in FY12 to ₹23,366.55 crore in FY22. Ten years ago, it was placed sixth (see table 'Coming from Behind").
So, how did the Hyderabad headquartered company reach such stratified air? Aurobindo has adopted a strategy of focussing on its forte of biosimilars (medicines that are highly similar to their branded reference medicines) along with gradually advancing in speciality pharmaceuticals (large, injectable, protein-based molecules, or small molecules used to treat complex conditions such as cancer and hepatitis C or common chronic diseases such as rheumatoid arthritis and asthma). It is making steady progress in developing biosimilars in the oncology and immunology segments, even as it has products in the pipeline for rheumatology, dermatology, ophthalmology and respiratory disease treatments, says K. Nithyananda Reddy, Co-founder and Vice Chairman. "We are targeting a market opportunity of over $50 billion. We have a mix of biosimilar products in the pipeline," he says.
As other manufacturers also crowd the biosimilars space, Aurobindo is looking at diversifying towards the speciality disease business. And its export markets are crucial to its strategy of diversifying towards high-margin speciality generic (non-branded) formulations and the speciality diseases segment.
Denne historien er fra September 18, 2022-utgaven av Business Today India.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra September 18, 2022-utgaven av Business Today India.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Pension Scheme - Safety Net
The move to introduce the UPS has evoked mixed reactions. Analysts believe its funding will have limited impact on the fiscal math
The Reit Choice?
Real Estate Investment Trusts (Reits) Are Gaining Traction As Interest Rates Stabilise. But Returns Could Be Affected By Adverse Economic Conditions And Market Volatility
CORPORATE - Calling to Account
The sudden exit of Byju's auditor BDO marks the latest in a long series of setbacks for the edtech firm
EMPLOYMENT: Skills Push
The skill development ministry plans to partner with the UGC to improve the employability of undergraduates
Building on a Vision
L&T'S CHAIRMAN EMERITUS A. M. NAIK HAS BUILT A MAMMOTH ENTERPRISE THAT IS BUILDING A NEW INDIA, FROM ITS METRO RAIL SYSTEMS TO THE RAM TEMPLE
"KYS more important than KYC"
Vijay Kedia is a renowned equity investor; the value of his listed portfolio stands at around ₹1,750 crore
ROXX STAR
THE THAR ROXX COMBINES LUXURY WITH PERFORMANCE TO MAKE A STRONG STATEMENT IN THE MID-SIZE SUV SEGMENT
HIT THE GROUND RUNNING
Smartwatches have become indispensable tools for runners, offering real-time insights into pace, distance, heart rate, and more. Here are a few you can consider
TURNING THE TABLES
INDIA'S FURNITURE MARKET IS POISED FOR A GLOBAL TAKE-OFF. ALREADY, A HOST OF GLOBAL BRANDS HAVE MADE THE COUNTRY THEIR HOME, BUT INDIAN COMPANIES ARE NOT TOO FAR BEHIND
THE EVOLUTION OF ATHERA
IDENTIFYING OPPORTUNITIES IN ADVANCE HAS STOOD THIS BENGALURU-BASED VC FUND IN GOOD STEAD. NOW, WITH A HEIGHTENED FOCUS ON TECHNOLOGY, IT WANTS TO SUSTAIN THE SUCCESS